RA Capital Management, L.P. and related reporting persons filed a Form 4 on November 18, 2026, disclosing the purchase of 1,000 shares of SpyGlass Pharma, Inc. common stock on November 16, 2026, at a weighted average price of $32.43 per share.
Key Highlights
- Transaction: 1,000 shares of common stock acquired (transaction code P) on November 16, 2026, at a weighted average price of $32.43 per share.
- Price range: Shares were purchased in multiple transactions at prices ranging from $32.42 to $32.60, inclusive.
- Post-transaction holdings: RA Capital Healthcare Fund, L.P. beneficially owns 5,967,439 shares; RA Capital Nexus Fund III, L.P. beneficially owns 2,054,678 shares, both held indirectly.
- Reporting persons: Five reporting persons joined in the filing: RA Capital Management, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Peter Kolchinsky; and Rajeev Shah.
- Roles: RA Capital Management, L.P., RA Capital Healthcare Fund LP, Peter Kolchinsky, and Rajeev Shah are each identified as both Director and 10% Owner; RA Capital Nexus Fund III, L.P. is identified as a Director.
- Board presence: According to the filing's remarks, Dr. Zachary Scheiner, a Principal of the Adviser, serves on the issuer's board of directors.
RA Capital's November 16 Open-Market Purchase of SpyGlass Pharma Common Stock
According to the Form 4 filed with the SEC on November 18, 2026, RA Capital Management, L.P. and four affiliated reporting persons reported a purchase of 1,000 shares of SpyGlass Pharma, Inc. (NASDAQ:SGP) common stock on November 16, 2026. The filing states that the reported price of $32.43 is a weighted average, and that the shares were acquired across multiple transactions at prices ranging from $32.42 to $32.60, inclusive. The reporting persons noted they will provide full details on shares purchased at each separate price upon request by the issuer, any security holder, or SEC staff.
The filing identifies RA Capital Management, L.P. as the investment adviser for RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund III, L.P. Peter Kolchinsky and Rajeev Shah are identified as the managing members of RA Capital Management GP, LLC, the general partner of the Adviser. The filing states that the 1,000 acquired shares are held directly by RA Capital Healthcare Fund, L.P., bringing that fund's reported beneficial ownership to 5,967,439 shares. RA Capital Nexus Fund III, L.P. is separately reported as beneficially owning 2,054,678 shares, with no transaction recorded for that fund in this filing.
The filing notes that each reporting person disclaims beneficial ownership of the reported securities "except to the extent of their pecuniary interest therein." The remarks section discloses that Dr. Zachary Scheiner, identified as a Principal of the Adviser, serves on SpyGlass Pharma's board of directors. The form was signed by Peter Kolchinsky on behalf of himself, RA Capital Management, L.P., RA Capital Healthcare Fund GP, LLC, and RA Capital Nexus Fund III GP, LLC, and separately by Rajeev Shah individually, all dated November 18, 2026.
What Was Disclosed
RA Capital Management, L.P. and four affiliated persons filed a joint Form 4 reporting the purchase of 1,000 shares of SpyGlass Pharma common stock at a weighted average price of $32.43 on November 16, 2026, with post-transaction beneficial ownership of 5,967,439 shares in the Healthcare Fund and 2,054,678 shares in Nexus Fund III.



Please wait processing your request...